celgosivir + zidovudine

Celgosivir + zidovudine is a combination of two small-molecule drugs with distinct but potentially complementary antiviral mechanisms, though this combination does not have an approved co-formulation or brand name. **Celgosivir** is an oral prodrug of castanospermine, functioning as an alpha-glucosidase I inhibitor, and has primarily been investigated for antiviral activity against flaviviruses such as dengue via host-directed inhibition of viral glycoprotein processing. **Zidovudine** (also known as azidothymidine, AZT, or ZDV) is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 replication by acting as a chain terminator during viral DNA synthesis. Zidovudine is approved and widely used in various fixed-dose combinations for HIV treatment and prevention, but celgosivir is investigational and not approved for HIV or any other indication. There is no evidence of a marketed or late-stage clinical product combining celgosivir and zidovudine for any disease[2][7].